Last reviewed · How we verify
Bicillin C-R (benzathine benzylpenicillin)
Bicillin C-R works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death.
Bicillin C-R, also known as benzathine benzylpenicillin, is a small molecule antibiotic developed by KING PHARMS in 1952. It is used to treat various bacterial infections, including Erysipelas, Pneumococcal pneumonia, and Syphilis, among others. Bicillin C-R is a benzathine benzylpenicillin, a type of penicillin antibiotic that works by inhibiting bacterial cell wall synthesis. It is currently owned by KING PHARMS and has been FDA-approved for its indications. As an off-patent medication, Bicillin C-R is likely available as a generic product.
At a glance
| Generic name | benzathine benzylpenicillin |
|---|---|
| Sponsor | Pfizer |
| Drug class | benzathine benzylpenicillin |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1952 |
Mechanism of action
Mechanism of Action. Penicillin exerts bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable.
Approved indications
- Erysipelas
- Pneumococcal pneumonia
- Pneumonia due to Streptococcus
- Scarlet fever
- Streptococcal infectious disease
- Streptococcus pyogenes infection
- Syphilis excluding neurosyphilis
Boxed warnings
- WARNING: NOT FOR INTRAVENOUS USE. DO NOT INJECT INTRAVENOUSLY OR ADMIX WITH OTHER INTRAVENOUS SOLUTIONS. THERE HAVE BEEN REPORTS OF INADVERTENT INTRAVENOUS ADMINISTRATION OF PENICILLIN G BENZATHINE WHICH HAS BEEN ASSOCIATED WITH CARDIORESPIRATORY ARREST AND DEATH. Prior to administration of this drug, carefully read the WARNINGS , ADVERSE REACTIONS , and DOSAGE AND ADMINISTRATION sections of the labeling.
Common side effects
- Cardiac arrest
- Pulmonary embolism
- Cerebrovascular accident
- Renal failure
- Intestinal necrosis
- Neurogenic bladder
- Hematuria
- Proteinuria
- Hypersensitivity reactions
- Pulmonary hypertension
- Vasovagal reaction
- Seizures
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial (PHASE2)
- Linezolid for Syphilis Pilot Study (PHASE2)
- Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates (PHASE4)
- Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline (PHASE4)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bicillin C-R CI brief — competitive landscape report
- Bicillin C-R updates RSS · CI watch RSS
- Pfizer portfolio CI